Targeted Radiotherapy Drug Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Targeted Radiotherapy Drug market size was valued at USD 6075.9 million in 2022 and is forecast to a readjusted size of USD 8868.3 million by 2029 with a CAGR of 5.6% during review period.

Targeted radiotherapy is a medical treatment designed to direct radioactive isotopes to specific types of tumor cells or tumor markers, allowing for precise tumor treatment. These drugs offer a promising treatment for some malignant tumors, especially those that are advanced or difficult to surgically remove. As technology develops, treatment effects, as well as patient survival and quality of life after treatment, can be better monitored and evaluated. The development trend of targeted radiotherapy drugs emphasizes precise treatment, personalized treatment and comprehensive treatment methods. This will hopefully provide more effective cancer treatments in the future and improve patient survival and quality of life.

Report includes an overview of the development of the Targeted Radiotherapy Drug industry chain, the market status of General Hospital (Radioactive Iodine Therapeutic Drugs, Radioactive Antibody Therapeutic Drugs), Specialty Hospital (Radioactive Iodine Therapeutic Drugs, Radioactive Antibody Therapeutic Drugs), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Targeted Radiotherapy Drug.

Regionally, the report analyzes the Targeted Radiotherapy Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Targeted Radiotherapy Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Targeted Radiotherapy Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Targeted Radiotherapy Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Radioactive Iodine Therapeutic Drugs, Radioactive Antibody Therapeutic Drugs).

Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Targeted Radiotherapy Drug market.

Regional Analysis: The report involves examining the Targeted Radiotherapy Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Targeted Radiotherapy Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Targeted Radiotherapy Drug:

Company Analysis: Report covers individual Targeted Radiotherapy Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Targeted Radiotherapy Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (General Hospital, Specialty Hospital).

Technology Analysis: Report covers specific technologies relevant to Targeted Radiotherapy Drug. It assesses the current state, advancements, and potential future developments in Targeted Radiotherapy Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Targeted Radiotherapy Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

   Novartis
   Bayer
   Endocyte
   Progenics Pharmaceuticals
   Jubilant Radiopharma
   Curium
   Fermi Energia
   Nucleus RadioPharma

   Radioactive Iodine Therapeutic Drugs
   Radioactive Antibody Therapeutic Drugs
   Others

   General Hospital
   Specialty Hospital

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the Targeted Radiotherapy Drug Market in 2025?

The growth of personalized medicine, advancements in radiotherapy technology, and the increasing number of FDA-approved targeted radiotherapy drugs are key strengths. There’s also growing awareness among patients and healthcare providers about the benefits of targeted therapies in treating cancer with fewer side effects.

What are the weaknesses of the Targeted Radiotherapy Drug Market in 2025?

High treatment costs, complex manufacturing processes, and limited availability of targeted radiotherapy drugs in emerging markets may hinder growth. The market also faces challenges related to regulatory hurdles and long approval timelines, impacting rapid deployment.

What opportunities exist for the Targeted Radiotherapy Drug Market in 2025?

Opportunities lie in expanding the range of cancers treatable with targeted radiotherapy, improving patient outcomes, and increasing collaborations between pharmaceutical companies and research institutions. Additionally, the rising demand for non-invasive treatment options and the potential of AI integration for better precision in treatment planning offer exciting prospects.

What threats could impact the Targeted Radiotherapy Drug Market in 2025?

The market could face threats from alternative cancer treatments like immunotherapy and chemotherapy. Moreover, market saturation, price pressures, and the risk of regulatory changes or pricing constraints from healthcare policies could affect profitability and market growth.

What are the political factors affecting the Targeted Radiotherapy Drug Market in 2025?

Government healthcare policies, regulatory approvals, and reimbursement frameworks significantly influence the market. Political stability in key markets and government funding for cancer research also play a role in driving or restricting the growth of targeted radiotherapy drugs.

How do economic factors impact the Targeted Radiotherapy Drug Market in 2025?

Economic conditions influence healthcare spending and the affordability of advanced treatments. Economic instability may lead to reduced investment in healthcare innovation, while rising income levels in emerging markets can increase demand for high-cost therapies like targeted radiotherapy drugs.

What are the social factors influencing the Targeted Radiotherapy Drug Market in 2025?

Growing public awareness of cancer and the benefits of targeted therapies is driving demand. As patients become more educated about treatment options, there’s an increasing preference for personalized and less invasive therapies. However, social disparities in access to treatment across regions could limit market growth.

What are the technological factors impacting the Targeted Radiotherapy Drug Market in 2025?

Technological advancements in radiotherapy devices, better drug delivery mechanisms, and AI-driven treatment planning are key drivers. Improved imaging techniques and precision medicine also enhance the effectiveness of targeted radiotherapy, leading to better outcomes and broader adoption.

What environmental factors are relevant to the Targeted Radiotherapy Drug Market in 2025?

Environmental concerns around sustainable manufacturing processes and the disposal of radioactive materials are critical. There is also growing pressure for eco-friendly packaging and reducing the carbon footprint of production processes. Strict environmental regulations may also affect the production and distribution of these drugs.

What are the legal factors affecting the Targeted Radiotherapy Drug Market in 2025?

Stringent regulations surrounding drug approval, clinical trials, and patent protection are crucial. Legal challenges related to intellectual property rights, product liability, and pricing regulations can impact the market’s competitiveness and accessibility. Ensuring compliance with healthcare laws is vital for the market’s continued growth.

Who are the suppliers in the Targeted Radiotherapy Drug Market in 2025?

Suppliers include pharmaceutical companies, biotechnology firms, manufacturers of radiotherapy equipment, and raw material suppliers for drug formulation. Additionally, research institutions and contract research organizations (CROs) contribute to the development and testing of targeted radiotherapy drugs.

What are the inputs for the Targeted Radiotherapy Drug Market in 2025?

Inputs include advanced research and development, raw materials for drug production, radiotherapy devices, skilled workforce, and data from clinical trials. Regulatory approvals and funding from investors and healthcare systems are also essential inputs.

What processes are involved in the Targeted Radiotherapy Drug Market in 2025?

The processes involve drug discovery and development, clinical trials, regulatory approvals, manufacturing, distribution, and marketing. Additionally, continuous monitoring of patient outcomes and post-market surveillance are important processes for ensuring the effectiveness and safety of the drugs.

Who are the customers in the Targeted Radiotherapy Drug Market in 2025?

Customers include healthcare providers, such as hospitals and oncology clinics, who administer the treatments. Additionally, insurance companies, government healthcare programs, and patients are key customers, with patients often driving demand for personalized cancer treatments.

What are the outputs of the Targeted Radiotherapy Drug Market in 2025?

The outputs include FDA-approved targeted radiotherapy drugs, treatment protocols, patient outcomes, and clinical research findings. Additionally, companies may produce data and insights for further drug development and market expansion.

How strong is the threat of new entrants in the Targeted Radiotherapy Drug Market in 2025?

The threat is moderate. While the high cost of research, development, and regulatory approval creates significant barriers to entry, the increasing demand for innovative cancer treatments attracts new players, including biotech startups and established pharmaceutical companies expanding into oncology.

How intense is the rivalry among existing competitors in the Targeted Radiotherapy Drug Market in 2025?

The rivalry is high. With many major pharmaceutical companies investing in targeted therapies, the market is competitive. Companies strive to differentiate their drugs based on effectiveness, precision, and fewer side effects. Intellectual property protection and the race for FDA approvals further intensify competition.

What is the bargaining power of suppliers in the Targeted Radiotherapy Drug Market in 2025?

The bargaining power of suppliers is moderate. While key suppliers of raw materials and technologies have some influence, the growing number of pharmaceutical companies and advancements in manufacturing processes have increased the number of available suppliers, somewhat reducing their bargaining power.

What is the bargaining power of buyers in the Targeted Radiotherapy Drug Market in 2025?

The bargaining power of buyers is moderate to high. Hospitals, healthcare providers, and insurance companies often negotiate prices and treatment protocols, while patients are increasingly informed about treatment options. However, due to the specialized nature of targeted therapies, there is limited buyer power in some cases.

How significant is the threat of substitute products in the Targeted Radiotherapy Drug Market in 2025?

The threat is moderate. While alternative cancer treatments like chemotherapy and immunotherapy are available, targeted radiotherapy drugs offer unique advantages in terms of precision and fewer side effects. However, the development of new and more effective alternatives could pose a future threat to market growth.

What are the key raw materials required for the Targeted Radiotherapy Drug Market in 2025?

Key raw materials include radioactive isotopes, chemical reagents for drug formulation, and materials used in the production of radiotherapy devices. Additionally, specialized equipment for imaging and drug delivery systems are essential components of the supply chain.

How do suppliers of raw materials influence the Targeted Radiotherapy Drug Market in 2025?

Suppliers of raw materials play a crucial role in ensuring the quality and availability of components needed for both drug production and radiotherapy equipment. Delays or shortages in the supply of radioactive isotopes or specialized chemicals could hinder drug manufacturing and market growth.

What are the regulatory requirements for upstream activities in the Targeted Radiotherapy Drug Market in 2025?

Upstream activities are heavily influenced by regulatory requirements such as FDA approval for drug development and production, safety standards for radioactive materials, and compliance with Good Manufacturing Practices (GMP). These regulations ensure the safety, efficacy, and quality of both drugs and radiotherapy devices.

How do research and development activities impact the upstream market in 2025?

R&D is a key driver for upstream activities. It leads to the discovery of novel compounds, better drug delivery methods, and innovative radiotherapy technologies. Collaboration between pharmaceutical companies, academic institutions, and suppliers is essential to drive progress and ensure a steady supply of new, effective treatments.

How does the competitive landscape of upstream suppliers affect the Targeted Radiotherapy Drug Market in 2025?

The competitive landscape of upstream suppliers influences the cost, quality, and availability of raw materials. Suppliers that offer advanced technologies, cost-effective production methods, and reliable delivery can help reduce production costs for pharmaceutical companies, while also driving innovation in drug formulation and radiotherapy devices.

What are the key activities involved in the midstream of the Targeted Radiotherapy Drug Market in 2025?

Key midstream activities include drug manufacturing, packaging, and the distribution of both the radiotherapy drugs and the associated equipment used in treatment. This stage also involves the formulation of the drug, ensuring proper labeling, and the logistics of delivering it to healthcare providers.

How does manufacturing capacity impact the midstream of the Targeted Radiotherapy Drug Market in 2025?

Manufacturing capacity directly impacts the ability to meet growing demand for targeted radiotherapy drugs. Limited capacity or inefficiencies in production could lead to supply shortages, increased costs, and delays in bringing new drugs to market. Scaling up production capabilities is essential to ensure a smooth flow from development to distribution.

What role does distribution play in the midstream of the Targeted Radiotherapy Drug Market in 2025?

Distribution plays a pivotal role in ensuring that targeted radiotherapy drugs and devices reach hospitals, oncology centers, and healthcare providers in a timely manner. Efficient logistics, cold chain management (for drugs requiring specific temperature control), and a reliable distribution network are crucial to maintaining supply consistency.

How do partnerships influence the midstream of the Targeted Radiotherapy Drug Market in 2025?

Partnerships between drug manufacturers, distributors, and healthcare providers are critical in improving market reach and ensuring drug availability. Collaborations with logistics companies and third-party distributors also help streamline operations, reducing costs and improving time-to-market for new therapies.

What challenges does the midstream face in the Targeted Radiotherapy Drug Market in 2025?

Challenges include managing the complexity of transporting and handling radioactive materials, ensuring regulatory compliance during distribution, and addressing potential delays in manufacturing or packaging. Additionally, scaling production to meet increasing demand and optimizing supply chain management are ongoing concerns.

What are the key activities involved in the downstream of the Targeted Radiotherapy Drug Market in 2025?

Key downstream activities include the administration of targeted radiotherapy treatments by healthcare providers, patient monitoring, follow-up care, and the collection of post-treatment data. Additionally, patient education and counseling on the benefits and potential side effects of treatment play a significant role in the downstream process.

How do healthcare providers impact the downstream of the Targeted Radiotherapy Drug Market in 2025?

Healthcare providers, including oncologists and radiologists, are crucial in prescribing, administering, and monitoring targeted radiotherapy treatments. Their expertise in personalized medicine and their ability to manage complex patient cases directly affect treatment outcomes, patient satisfaction, and market adoption.

What role does patient access to treatment play in the downstream of the Targeted Radiotherapy Drug Market in 2025?

Patient access is critical. Healthcare systems and insurance companies often dictate the affordability and availability of targeted radiotherapy treatments. Variations in insurance coverage and regional healthcare infrastructure can influence the rate of adoption and the reach of targeted therapies.

How do reimbursement policies affect the downstream of the Targeted Radiotherapy Drug Market in 2025?

Reimbursement policies greatly affect patient access and the affordability of treatments. Policies that cover targeted radiotherapy drugs can drive adoption, whereas limited coverage or complex reimbursement processes may deter healthcare providers from offering these treatments, ultimately slowing market growth.

What challenges does the downstream face in the Targeted Radiotherapy Drug Market in 2025?

Challenges include ensuring equitable access to treatments, managing high treatment costs, and addressing variations in healthcare infrastructure across regions. There is also the challenge of educating patients and providers about the benefits and proper usage of targeted therapies, especially in underserved areas.

Chapter 1, to describe Targeted Radiotherapy Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Radiotherapy Drug, with revenue, gross margin and global market share of Targeted Radiotherapy Drug from 2018 to 2023.
Chapter 3, the Targeted Radiotherapy Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Targeted Radiotherapy Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Radiotherapy Drug.
Chapter 13, to describe Targeted Radiotherapy Drug research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Targeted Radiotherapy Drug
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Targeted Radiotherapy Drug by Type
       1.3.1 Overview: Global Targeted Radiotherapy Drug Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Targeted Radiotherapy Drug Consumption Value Market Share by Type in 2022
       1.3.3 Radioactive Iodine Therapeutic Drugs
       1.3.4 Radioactive Antibody Therapeutic Drugs
       1.3.5 Others
   1.4 Global Targeted Radiotherapy Drug Market by Application
       1.4.1 Overview: Global Targeted Radiotherapy Drug Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 General Hospital
       1.4.3 Specialty Hospital
   1.5 Global Targeted Radiotherapy Drug Market Size & Forecast
   1.6 Global Targeted Radiotherapy Drug Market Size and Forecast by Region
       1.6.1 Global Targeted Radiotherapy Drug Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Targeted Radiotherapy Drug Market Size by Region, (2018-2029)
       1.6.3 North America Targeted Radiotherapy Drug Market Size and Prospect (2018-2029)
       1.6.4 Europe Targeted Radiotherapy Drug Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Targeted Radiotherapy Drug Market Size and Prospect (2018-2029)
       1.6.6 South America Targeted Radiotherapy Drug Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Targeted Radiotherapy Drug Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Novartis
       2.1.1 Novartis Details
       2.1.2 Novartis Major Business
       2.1.3 Novartis Targeted Radiotherapy Drug Product and Solutions
       2.1.4 Novartis Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Novartis Recent Developments and Future Plans
   2.2 Bayer
       2.2.1 Bayer Details
       2.2.2 Bayer Major Business
       2.2.3 Bayer Targeted Radiotherapy Drug Product and Solutions
       2.2.4 Bayer Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Bayer Recent Developments and Future Plans
   2.3 Endocyte
       2.3.1 Endocyte Details
       2.3.2 Endocyte Major Business
       2.3.3 Endocyte Targeted Radiotherapy Drug Product and Solutions
       2.3.4 Endocyte Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Endocyte Recent Developments and Future Plans
   2.4 Progenics Pharmaceuticals
       2.4.1 Progenics Pharmaceuticals Details
       2.4.2 Progenics Pharmaceuticals Major Business
       2.4.3 Progenics Pharmaceuticals Targeted Radiotherapy Drug Product and Solutions
       2.4.4 Progenics Pharmaceuticals Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Progenics Pharmaceuticals Recent Developments and Future Plans
   2.5 Jubilant Radiopharma
       2.5.1 Jubilant Radiopharma Details
       2.5.2 Jubilant Radiopharma Major Business
       2.5.3 Jubilant Radiopharma Targeted Radiotherapy Drug Product and Solutions
       2.5.4 Jubilant Radiopharma Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Jubilant Radiopharma Recent Developments and Future Plans
   2.6 Curium
       2.6.1 Curium Details
       2.6.2 Curium Major Business
       2.6.3 Curium Targeted Radiotherapy Drug Product and Solutions
       2.6.4 Curium Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Curium Recent Developments and Future Plans
   2.7 Fermi Energia
       2.7.1 Fermi Energia Details
       2.7.2 Fermi Energia Major Business
       2.7.3 Fermi Energia Targeted Radiotherapy Drug Product and Solutions
       2.7.4 Fermi Energia Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Fermi Energia Recent Developments and Future Plans
   2.8 Nucleus RadioPharma
       2.8.1 Nucleus RadioPharma Details
       2.8.2 Nucleus RadioPharma Major Business
       2.8.3 Nucleus RadioPharma Targeted Radiotherapy Drug Product and Solutions
       2.8.4 Nucleus RadioPharma Targeted Radiotherapy Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Nucleus RadioPharma Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Targeted Radiotherapy Drug Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Targeted Radiotherapy Drug by Company Revenue
       3.2.2 Top 3 Targeted Radiotherapy Drug Players Market Share in 2022
       3.2.3 Top 6 Targeted Radiotherapy Drug Players Market Share in 2022
   3.3 Targeted Radiotherapy Drug Market: Overall Company Footprint Analysis
       3.3.1 Targeted Radiotherapy Drug Market: Region Footprint
       3.3.2 Targeted Radiotherapy Drug Market: Company Product Type Footprint
       3.3.3 Targeted Radiotherapy Drug Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Targeted Radiotherapy Drug Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Targeted Radiotherapy Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2023)
   5.2 Global Targeted Radiotherapy Drug Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Targeted Radiotherapy Drug Consumption Value by Type (2018-2029)
   6.2 North America Targeted Radiotherapy Drug Consumption Value by Application (2018-2029)
   6.3 North America Targeted Radiotherapy Drug Market Size by Country
       6.3.1 North America Targeted Radiotherapy Drug Consumption Value by Country (2018-2029)
       6.3.2 United States Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       6.3.3 Canada Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       6.3.4 Mexico Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Targeted Radiotherapy Drug Consumption Value by Type (2018-2029)
   7.2 Europe Targeted Radiotherapy Drug Consumption Value by Application (2018-2029)
   7.3 Europe Targeted Radiotherapy Drug Market Size by Country
       7.3.1 Europe Targeted Radiotherapy Drug Consumption Value by Country (2018-2029)
       7.3.2 Germany Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       7.3.3 France Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       7.3.5 Russia Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       7.3.6 Italy Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Targeted Radiotherapy Drug Market Size by Region
       8.3.1 Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Region (2018-2029)
       8.3.2 China Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       8.3.3 Japan Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       8.3.4 South Korea Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       8.3.5 India Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       8.3.7 Australia Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Targeted Radiotherapy Drug Consumption Value by Type (2018-2029)
   9.2 South America Targeted Radiotherapy Drug Consumption Value by Application (2018-2029)
   9.3 South America Targeted Radiotherapy Drug Market Size by Country
       9.3.1 South America Targeted Radiotherapy Drug Consumption Value by Country (2018-2029)
       9.3.2 Brazil Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       9.3.3 Argentina Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Targeted Radiotherapy Drug Market Size by Country
       10.3.1 Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Country (2018-2029)
       10.3.2 Turkey Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)
       10.3.4 UAE Targeted Radiotherapy Drug Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Targeted Radiotherapy Drug Market Drivers
   11.2 Targeted Radiotherapy Drug Market Restraints
   11.3 Targeted Radiotherapy Drug Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry

12 Industry Chain Analysis

   12.1 Targeted Radiotherapy Drug Industry Chain
   12.2 Targeted Radiotherapy Drug Upstream Analysis
   12.3 Targeted Radiotherapy Drug Midstream Analysis
   12.4 Targeted Radiotherapy Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Targeted Radiotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Targeted Radiotherapy Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Targeted Radiotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Targeted Radiotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Novartis Company Information, Head Office, and Major Competitors
   Table 6. Novartis Major Business
   Table 7. Novartis Targeted Radiotherapy Drug Product and Solutions
   Table 8. Novartis Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Novartis Recent Developments and Future Plans
   Table 10. Bayer Company Information, Head Office, and Major Competitors
   Table 11. Bayer Major Business
   Table 12. Bayer Targeted Radiotherapy Drug Product and Solutions
   Table 13. Bayer Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Bayer Recent Developments and Future Plans
   Table 15. Endocyte Company Information, Head Office, and Major Competitors
   Table 16. Endocyte Major Business
   Table 17. Endocyte Targeted Radiotherapy Drug Product and Solutions
   Table 18. Endocyte Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Endocyte Recent Developments and Future Plans
   Table 20. Progenics Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 21. Progenics Pharmaceuticals Major Business
   Table 22. Progenics Pharmaceuticals Targeted Radiotherapy Drug Product and Solutions
   Table 23. Progenics Pharmaceuticals Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Progenics Pharmaceuticals Recent Developments and Future Plans
   Table 25. Jubilant Radiopharma Company Information, Head Office, and Major Competitors
   Table 26. Jubilant Radiopharma Major Business
   Table 27. Jubilant Radiopharma Targeted Radiotherapy Drug Product and Solutions
   Table 28. Jubilant Radiopharma Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Jubilant Radiopharma Recent Developments and Future Plans
   Table 30. Curium Company Information, Head Office, and Major Competitors
   Table 31. Curium Major Business
   Table 32. Curium Targeted Radiotherapy Drug Product and Solutions
   Table 33. Curium Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Curium Recent Developments and Future Plans
   Table 35. Fermi Energia Company Information, Head Office, and Major Competitors
   Table 36. Fermi Energia Major Business
   Table 37. Fermi Energia Targeted Radiotherapy Drug Product and Solutions
   Table 38. Fermi Energia Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Fermi Energia Recent Developments and Future Plans
   Table 40. Nucleus RadioPharma Company Information, Head Office, and Major Competitors
   Table 41. Nucleus RadioPharma Major Business
   Table 42. Nucleus RadioPharma Targeted Radiotherapy Drug Product and Solutions
   Table 43. Nucleus RadioPharma Targeted Radiotherapy Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Nucleus RadioPharma Recent Developments and Future Plans
   Table 45. Global Targeted Radiotherapy Drug Revenue (USD Million) by Players (2018-2023)
   Table 46. Global Targeted Radiotherapy Drug Revenue Share by Players (2018-2023)
   Table 47. Breakdown of Targeted Radiotherapy Drug by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 48. Market Position of Players in Targeted Radiotherapy Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 49. Head Office of Key Targeted Radiotherapy Drug Players
   Table 50. Targeted Radiotherapy Drug Market: Company Product Type Footprint
   Table 51. Targeted Radiotherapy Drug Market: Company Product Application Footprint
   Table 52. Targeted Radiotherapy Drug New Market Entrants and Barriers to Market Entry
   Table 53. Targeted Radiotherapy Drug Mergers, Acquisition, Agreements, and Collaborations
   Table 54. Global Targeted Radiotherapy Drug Consumption Value (USD Million) by Type (2018-2023)
   Table 55. Global Targeted Radiotherapy Drug Consumption Value Share by Type (2018-2023)
   Table 56. Global Targeted Radiotherapy Drug Consumption Value Forecast by Type (2024-2029)
   Table 57. Global Targeted Radiotherapy Drug Consumption Value by Application (2018-2023)
   Table 58. Global Targeted Radiotherapy Drug Consumption Value Forecast by Application (2024-2029)
   Table 59. North America Targeted Radiotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 60. North America Targeted Radiotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 61. North America Targeted Radiotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 62. North America Targeted Radiotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 63. North America Targeted Radiotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 64. North America Targeted Radiotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 65. Europe Targeted Radiotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 66. Europe Targeted Radiotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 67. Europe Targeted Radiotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 68. Europe Targeted Radiotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 69. Europe Targeted Radiotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 70. Europe Targeted Radiotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 71. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 72. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 73. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 74. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 75. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Region (2018-2023) & (USD Million)
   Table 76. Asia-Pacific Targeted Radiotherapy Drug Consumption Value by Region (2024-2029) & (USD Million)
   Table 77. South America Targeted Radiotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 78. South America Targeted Radiotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 79. South America Targeted Radiotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 80. South America Targeted Radiotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 81. South America Targeted Radiotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 82. South America Targeted Radiotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 83. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 84. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 85. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 86. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 87. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 88. Middle East & Africa Targeted Radiotherapy Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 89. Targeted Radiotherapy Drug Raw Material
   Table 90. Key Suppliers of Targeted Radiotherapy Drug Raw Materials

List of Figures

   Figure 1. Targeted Radiotherapy Drug Picture
   Figure 2. Global Targeted Radiotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Targeted Radiotherapy Drug Consumption Value Market Share by Type in 2022
   Figure 4. Radioactive Iodine Therapeutic Drugs
   Figure 5. Radioactive Antibody Therapeutic Drugs
   Figure 6. Others
   Figure 7. Global Targeted Radiotherapy Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 8. Targeted Radiotherapy Drug Consumption Value Market Share by Application in 2022
   Figure 9. General Hospital Picture
   Figure 10. Specialty Hospital Picture
   Figure 11. Global Targeted Radiotherapy Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Targeted Radiotherapy Drug Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Market Targeted Radiotherapy Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 14. Global Targeted Radiotherapy Drug Consumption Value Market Share by Region (2018-2029)
   Figure 15. Global Targeted Radiotherapy Drug Consumption Value Market Share by Region in 2022
   Figure 16. North America Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 17. Europe Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 18. Asia-Pacific Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 19. South America Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 20. Middle East and Africa Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 21. Global Targeted Radiotherapy Drug Revenue Share by Players in 2022
   Figure 22. Targeted Radiotherapy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 23. Global Top 3 Players Targeted Radiotherapy Drug Market Share in 2022
   Figure 24. Global Top 6 Players Targeted Radiotherapy Drug Market Share in 2022
   Figure 25. Global Targeted Radiotherapy Drug Consumption Value Share by Type (2018-2023)
   Figure 26. Global Targeted Radiotherapy Drug Market Share Forecast by Type (2024-2029)
   Figure 27. Global Targeted Radiotherapy Drug Consumption Value Share by Application (2018-2023)
   Figure 28. Global Targeted Radiotherapy Drug Market Share Forecast by Application (2024-2029)
   Figure 29. North America Targeted Radiotherapy Drug Consumption Value Market Share by Type (2018-2029)
   Figure 30. North America Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2029)
   Figure 31. North America Targeted Radiotherapy Drug Consumption Value Market Share by Country (2018-2029)
   Figure 32. United States Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 33. Canada Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 34. Mexico Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 35. Europe Targeted Radiotherapy Drug Consumption Value Market Share by Type (2018-2029)
   Figure 36. Europe Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2029)
   Figure 37. Europe Targeted Radiotherapy Drug Consumption Value Market Share by Country (2018-2029)
   Figure 38. Germany Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 39. France Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 40. United Kingdom Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 41. Russia Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 42. Italy Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 43. Asia-Pacific Targeted Radiotherapy Drug Consumption Value Market Share by Type (2018-2029)
   Figure 44. Asia-Pacific Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2029)
   Figure 45. Asia-Pacific Targeted Radiotherapy Drug Consumption Value Market Share by Region (2018-2029)
   Figure 46. China Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 47. Japan Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 48. South Korea Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 49. India Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 50. Southeast Asia Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 51. Australia Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 52. South America Targeted Radiotherapy Drug Consumption Value Market Share by Type (2018-2029)
   Figure 53. South America Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2029)
   Figure 54. South America Targeted Radiotherapy Drug Consumption Value Market Share by Country (2018-2029)
   Figure 55. Brazil Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 56. Argentina Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 57. Middle East and Africa Targeted Radiotherapy Drug Consumption Value Market Share by Type (2018-2029)
   Figure 58. Middle East and Africa Targeted Radiotherapy Drug Consumption Value Market Share by Application (2018-2029)
   Figure 59. Middle East and Africa Targeted Radiotherapy Drug Consumption Value Market Share by Country (2018-2029)
   Figure 60. Turkey Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 61. Saudi Arabia Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 62. UAE Targeted Radiotherapy Drug Consumption Value (2018-2029) & (USD Million)
   Figure 63. Targeted Radiotherapy Drug Market Drivers
   Figure 64. Targeted Radiotherapy Drug Market Restraints
   Figure 65. Targeted Radiotherapy Drug Market Trends
   Figure 66. Porters Five Forces Analysis
   Figure 67. Manufacturing Cost Structure Analysis of Targeted Radiotherapy Drug in 2022
   Figure 68. Manufacturing Process Analysis of Targeted Radiotherapy Drug
   Figure 69. Targeted Radiotherapy Drug Industrial Chain
   Figure 70. Methodology
   Figure 71. Research Process and Data Source